Pinealon — questions, answered plainly.

Pinealon is a synthetic tripeptide (Glu-Asp-Arg / EDR) developed by the Khavinson research group at the St Petersburg Institute of Bioregulation and Gerontology. It is part of the 'short peptide' family that the Khavinson group has published on for over two decades.

No. Pinealon is not FDA-approved, MHRA-approved, or EMA-approved. Published evidence is preclinical only.

Khavinson 2011 (Rejuvenation Research, PMID 21978084) reports Pinealon was associated with reduced free-radical signal and altered viability metrics in rat cerebellar granule cells, neutrophils, and PC12 cells. Arutjunyan 2012 (PMID 22803060) reports Pinealon administration reduced hyperhomocysteinemia-associated markers in rat offspring cerebellar tissue.

The Khavinson research network in St Petersburg has produced the majority of peer-reviewed Pinealon literature. Independent replication outside this network is limited; this is a documented evidence caveat rather than an editorial judgement.

Cited preclinical work attributes Pinealon activity to short-peptide gene-regulatory effects in cerebellar neurons and pineal-derived cells. Receptor identity and downstream signalling have not been fully characterised in peer-reviewed literature.

No controlled human trials are indexed on PubMed. All cited primary evidence originates from the Khavinson research network. Findings are model-specific (rodent and cell-culture) and are not extrapolated to therapeutic use.